Veracyte announced new data demonstrating that its next-generation Percepta® Genomic Sequencing Classifier (GSC) can provide improved lung cancer diagnosis. This test is the third clinical classifier to be developed on the company's novel RNA whole-transcriptome sequencing and machine learning platform. In fact, all of the company's patent documents in the AI Biotech/Diagnostics sector relate to molecular profiling. Veracyte will also present clinical utility data demonstrating that its Envisia™ Genomic Classifier improves diagnosis of idiopathic pulmonary fibrosis, which the company has a patent for as well.
Artificial intelligence and human health don’t stop with our general diagnostics, cardiology, neurology, and activity sectors. This sector covers AI/ML-centric advancements in auditory, dental, GI/hepatic, circulatory, immune, musculoskeletal, ocular, reproductive, respiratory, dermatological, urinary, rectal, and spectrometry related biotech.
View Patent Forecast®
Top Corporations
News and Insights
Data Visualization
Artificial intelligence and human health don’t stop with our general diagnostics, cardiology, neurology, and activity sectors. This sector covers AI/ML-centric advancements in auditory, dental, GI/hepatic, circulatory, immune, musculoskeletal, ocular, reproductive, respiratory, dermatological, urinary, rectal, and spectrometry related biotech.